AbbVie
ABBV · NYSE · USD · Healthcare
Price
+12.2% since 20/07/20263 months · High $291.40 (-3.0%) · Low $239.73
What is happening
AbbVie has fallen 3% since its 6-week high on 15/10/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayHow deep is the dip?
- from the 6-week high-3.0%
Highest daily price: $291.40 on 15/10/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-3.0%
Highest price in 52 weeks: $291.40 (Yahoo)
Marking places no order – it only helps you keep track.
Catalysts
3 h ago- News, last 10 days
- no recent news
- Next earnings
- 30/10/2026 · in 10 days
- Last report
- 31/07/2026 +1.1% vs estimate
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Headquarters:
- North Chicago, United States
- 52-week range:
- $190.75 – $291.40
- Website:
- abbvie.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
